PI
SAGE

PEAK6 Investments’s Sage Therapeutics SAGE Stock Holding History

PEAK6 Investments’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,000
Closed -$309K – 4767
2023
Q3 		$309K Buy
15,000
+6,000
+67% +$173K ﹤0.01% 2757
2023
Q2 		$423K Buy
9,000
+4,785
+114% +$238K ﹤0.01% 2328
2023
Q1 		$177K Buy
4,215
+1,070
+34% +$46K ﹤0.01% 3185
2022
Q4 		$120K Buy
+3,145
New +$120K ﹤0.01% 3563
2022
Q3 		– Sell
-9,000
Closed -$348K – 5541
2022
Q2 		$423K Buy
+9,000
New +$302K ﹤0.01% 2329
2020
Q1 		– Sell
-3,341
Closed -$241K – 4481
2019
Q4 		$241K Buy
3,341
+2,994
+863% +$368K ﹤0.01% 2435
2019
Q3 		$49K Buy
347
+106
+44% +$17.7K ﹤0.01% 3400
2019
Q2 		$44K Sell
241
-206
-46% -$35.1K ﹤0.01% 3346
2019
Q1 		$71K Sell
447
-745
-63% -$108K ﹤0.01% 3334
2018
Q4 		$114K Buy
1,192
+838
+237% +$95.9K ﹤0.01% 3344
2018
Q3 		$50K Buy
+354
New +$54.6K ﹤0.01% 3753

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PEAK6 Investments's SAGE Position: Q4 2023 in Review

PEAK6 Investments sold out of Sage Therapeutics (SAGE) in Q4 2023, closing a stake of 15,000 shares — an estimated $309K sold.

PEAK6 Investments first reported a position in SAGE in Q3 2018 and held it in 11 quarters. The position peaked at $423K in Q2 2023. 201 funds tracked by Wall St. Rank hold SAGE as of Q4 2023.

  • PEAK6 Investments reported no remaining Sage Therapeutics position as of Q4 2023 after selling out during the quarter.
  • PEAK6 Investments sold 15,000 Sage Therapeutics shares in Q4 2023, an estimated $309K.
  • PEAK6 Investments first reported a position in Sage Therapeutics in Q3 2018 and held it in 11 quarters.
  • PEAK6 Investments's Sage Therapeutics position peaked at $423K in Q2 2023.
  • 201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2023.

Based on PEAK6 Investments's 13F filing for Q4 2023, filed 13 Feb 2024.